Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases.
Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease.
Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer.
The company was incorporated in 2004 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 18, 24 | -0.13 Increased by +23.53% | -0.11 Decreased by -18.18% |
| Feb 7, 24 | -0.11 Increased by +35.29% | -0.14 Increased by +21.43% |
| Nov 27, 23 | -0.12 Increased by +33.33% | -0.15 Increased by +20.00% |
| Aug 8, 23 | -0.14 Increased by +12.50% | -0.17 Increased by +17.65% |
| May 9, 23 | -0.17 Decreased by -21.43% | -0.19 Increased by +10.53% |
| Feb 7, 23 | -0.17 Decreased by -21.43% | -0.19 Increased by +10.53% |
| Nov 28, 22 | -0.18 Decreased by -20.00% | -0.16 Decreased by -12.50% |
| Aug 9, 22 | -0.16 Decreased by -14.29% | -0.15 Decreased by -6.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.15 M Increased by +29.00% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -11.28 M Increased by +8.79% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -13.11 M Decreased by -25.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -12.97 M Decreased by -19.20% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -14.29 M Decreased by -21.95% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -12.37 M Decreased by -21.48% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -10.44 M Decreased by -27.99% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -10.88 M Decreased by -38.54% | Decreased by N/A% Decreased by N/A% |